A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Inclusion Criteria:

• Have hemoglobin A1c (HbA1c) <6.5%.

• Have a BMI of ≥30 kg/m2 OR ≥27 kg/m2 and <30 kg/m2 with at least 1 weight-relatedcomorbidity.

• Have a self-reported history of stable body weight for the 3 months prior torandomization (≤5% body weight change).

• Participants of childbearing potential must be non-pregnant and non-lactating andmust agree to use study-specified contraceptive methods.

Exclusion Criteria:

• Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetesmellitus (T2DM), or other forms of diabetes mellitus. A participant with a historyof gestational diabetes may be included in the study if the participant has an HbA1c < 6.5% at Screening.

• Have at least 1 laboratory value suggestive of diabetes during Screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L).

• Have had exposure to glucagon-like peptide -1 (GLP-1) 6 months prior to Screening orany prior history of known or suspected hypersensitivity/allergies, intolerability,or lack of efficacy to these medications. Have known or suspected hypersensitivityto study intervention(s), to selective GLP-1 receptor agonist (RA) orglucose-dependent insulinotropic peptide (GIP)/GLP-1 or GLP-1/glucagon (GCG) dualreceptor agonists.

• Pregnant or breastfeeding at Screening or planning to become pregnant (self orpartner) at any time within the dosing period, including follow -up, and for atleast 60 days after the last dose of study intervention.